the acurx pharmaceuticals ( n = 8) company is a small small group of small small small small small small men and is now in the lead optimization stage of preclinical development for the treatment of multi - drug resistant bacteria. this article reviews our financial results and its impact on the health of the patient. we also provide some important information on the current status of our drug and its potential for the development of a new class of antibiotics.